Prostate Cancer
23andMe Gains FDA Clearance for Direct-to-Consumer Prostate Cancer Genetic Risk Test
The firm is now authorized to sell a genetic health report on the HOXB13 marker that indicates risk for hereditary prostate cancer, its third DTC cancer risk report with 510(k) clearance.
FDA Clears Jubilant Therapeutics' IND Allowing for LSD1/HDAC6 Inhibitor Clinical Trial
The company will evaluate JBI-802 in solid tumors, including small cell lung cancer and treatment-induced neuroendocrine prostate cancer.
Ahead of an expected radiopharmaceutical approval in the New Year, oncologists and drugmakers are taking stock of imaging eligibility requirements and access disparities.
Rarecells Raises $13M in Series A Round to Develop Liquid Biopsy Early Cancer Detection Tests
The company is planning to develop circulating tumor cell assays for prostate cancer and acute myeloid leukemia and to launch them in the US.
Black and male patients had lower awareness of genetic risk of cancer and germline testing, as did patients with higher cancer fatalism and less confidence with medical materials.